Anti-amyloid antibody therapies in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
After years of failed attempts to develop a disease-modifying therapy for Alzheimer’s disease, consistent evidence in support of clinical efficacy was finally presented for a monoclonal antibody targeting the amyloid-β protofibrils. In addition to meeting the primary outcome of slowing clinical disease progression over 18 months, secondary clinical outcomes and amyloid-β lowering on PET also underpin the positive results of the trial. In this opinion piece, we highlight the key characteristics of the previous unsuccessful trials and analyse the potential reasons why those attempts to develop a treatment for early Alzheimer’s disease failed. We compare the safety profiles of the different antibodies and highlight cautionary measures for their routine clinical use. Last, we discuss the role of blood-based biomarkers in transforming the clinical care pathway to facilitate the uptake of antibody treatments, proposing an integrated case-finding and treatment model crossing the different healthcare sectors. Taken together, a real breakthrough may have been achieved by proving that amyloid-β reduction results in clinical benefits, rather than just biomarker changes. At the same time, routine use of the new generation of drugs will show if statistical efficacy translates into clinically meaningful change. This may just be the beginning of a new era of Alzheimer’s disease drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Cummings, J., Osse, A. M. L., Cammann, D., Powell, J., & Chen, J. (2024) · BioDrugs · doi:10.1007/s40259-023-00633-2 · Cited by 368
“Reaching the threshold of Aβ reduction required for slowing of disease progression is dose-related; trials with higher doses were more likely to attain the required decrease in Aβ burden [74].”
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 202
Anti‐amyloid antibody treatments for Alzheimer's disease
Perneczky, R., Dom, G., Chan, A., Falkai, P., & Bassetti, C. (2024) · European Journal of Neurology · doi:10.1111/ene.16049 · Cited by 106
Self-citationAmyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Rabinovici, G. D., & La Joie, R. (2023) · JAMA · doi:10.1001/jama.2023.11703 · Cited by 80
Aβ-oligomers: A potential therapeutic target for Alzheimer's disease
Ghosh, S., Ali, R., & Verma, S. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124231 · Cited by 87
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 90
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease
Kurkinen, M. T. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/171379 · Cited by 90
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research
Iaccarino, L., Burnham, S. C., Tunali, I., Wang, J., Navitsky, M. A., Arora, A., & Pontecorvo, M. J. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103765 · Cited by 74
Once upon a time, the Amyloid Cascade Hypothesis
Granzotto, A., & Sensi, S. L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102161 · Cited by 57
Maniv, I., Sarji, M., Bdarneh, A., Feldman, A., Ankawa, R., Koren, E., Magid-Gold, I., Reis, N., Soteriou, D., Salomon‐Zimri, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41545-7 · Cited by 56
Sharma, A., Rudrawar, S., Bharate, S. B., & Jadhav, H. R. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00630e · Cited by 70
Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches
Gholami, A. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137532 · Cited by 59
Impact of Microbiome–Brain Communication on Neuroinflammation and Neurodegeneration
Stolzer, I., Scherer, E., Süß, P., Rothhammer, V., Winner, B., Neurath, M. F., & Günther, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914925 · Cited by 49
“The ongoing endeavors in research are directed toward the creation of disease-modifying treatments that possess the capability to either halt or decelerate the advancement of AD [45–47].”
Restoration of metal homeostasis: a potential strategy against neurodegenerative diseases
Zhang, Y., Li, X., Ren, K., Peng, J., & Luo, X. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101931 · Cited by 48
Collij, L. E., Bischof, G. N., Altomare, D., Bader, I., Battle, M. R., García, D. V., Alves, I. L., Wolz, R., Gismondi, R., Stephens, A. W., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268119 · Cited by 54
Silva, R. O., Counil, H., Rabanel, J., Haddad, M., Zaouter, C., Khedher, M. R. B., Patten, S. A., & Ramassamy, C. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s449227 · Cited by 53
“5 However, until recently, very limited clinical efficacy based on the anti-amyloid-β immunotherapy have provided beneficial effects in AD.”
BackgroundsiRNA drug delivery across the blood–brain barrier in Alzheimer's disease
Sajid, M. I., Sheikh, F. S., Anis, F., Nasim, N., Sumbria, R. K., Nauli, S. M., & Tiwari, R. K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114968 · Cited by 59
Advancements in neurodegenerative diseases: Pathogenesis and novel neurorestorative interventions
Gao, W., Jing, S., He, C., Saberi, H., Sharma, H. S., Han, F., & Chen, L. (2024) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2024.100176 · Cited by 47
Li, W., Xu, L., Wang, S., Wang, Y., Pan, Y., Shi, L., & Guo, D. (2024) · Advanced Materials · doi:10.1002/adma.202401918 · Cited by 41
Joie, R. L., Cummings, J. L., Dage, J. L., Galasko, D. R., Ikonomović, M. D., Karikari, T. K., Landau, S. M., Llibre‐Guerra, J. J., Mummery, C. J., Ossenkoppele, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70997 · Cited by 38
Chen, Y., Yang, X., Li, J., Luo, H., Huang, Q., Yang, W., Lei, T., Lü, Y., Gong, Q., Li, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113604 · Cited by 30
Osteoporosis and Alzheimer´s disease (or Alzheimer´s disease and Osteoporosis)
Wanionok, N. E., Morel, G. R., & Fernández, J. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102408 · Cited by 32
Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2024) · Brain · doi:10.1093/brain/awae216 · Cited by 38
Zhuang, X., Jie, L., Song, Y., Ban, R., Zhao, X., Xia, Z., Wang, Z., & Zhang, G. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08815-z · Cited by 35
“While it successfully reduces amyloid plaque buildup, concerns about amyloid-related imaging abnormalities (ARIA) and inconsistent clinical benefits have limited its use (Ameen et al., 2024; Grover & Jain, 2022; Perneczky et al., 2023).”
Tonegawa‐Kuji, R., Hou, Y., Hu, B., Lorincz‐Comi, N. J., Pieper, A. A., Tousi, B., Leverenz, J. B., & Cheng, F. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004568 · Cited by 36
“Abnormal amyloid-beta (Aβ) deposition in the brain is a key pathological hallmark of AD and one of the major targets in AD research and drug development [1].”
Central Nervous System Targeted Protein Degraders
Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023) · Biomolecules · doi:10.3390/biom13081164 · Cited by 30
“Small molecule drugs still dominate brain-targeted therapies, but interest in gene-based and antibody treatments is rising to address the disease burden [2,3].”
BackgroundMahjoubi, M. A., Lamrani, D., Saleh, S., Moutaouakil, W., Ouhmida, A., Hamida, S., Cherradi, B., & Raihani, A. (2025) · Intelligence-Based Medicine · doi:10.1016/j.ibmed.2025.100219 · Cited by 34
Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy
Mahboob, A., Ali, H., Naimi, A. J. A., Yousef, M., Rob, M., Al-Muhannadi, N. A., Senevirathne, D. K. L., & Châari, A. (2024) · Cells · doi:10.3390/cells13181527 · Cited by 30
Hackett, K., Xu, S., McKniff, M., Paglia, L., Barnett, I., & Giovannetti, T. (2024) · JMIR Human Factors · doi:10.2196/59974 · Cited by 33
An Alternative View of Familial Alzheimer’s Disease Genetics
Lardelli, M. T. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230313 · Cited by 24
Targeting brain‐derived neurotrophic factor in the treatment of neurodegenerative diseases: A review
Wang, D., Lang, Z., Wei, S., Wang, W., & Zhang, H. (2024) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.43 · Cited by 31
Marković, M., Milošević, J. R., Wang, W., & Cao, Y. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.123.000726 · Cited by 24
Lewkowicz, E., Nakamura, M. N., Rynkiewicz, M. J., & Gursky, O. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05026-w · Cited by 22
“Emerging therapeutic strategies for AD target Aβ amyloid [5].”
BackgroundElbatrawy, A. A., Ademoye, T. A., Alnakhala, H., Tripathi, A., Zami, A., Ostafe, R., Dettmer, U., & Fortin, J. S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117613 · Cited by 20
Logroscino, G., Urso, D., Gnoni, V., Giugno, A., Vilella, D., Castri, A. D., Barone, R. M. E., Nigro, S. L., Zecca, C., Blasi, R. D., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16534 · Cited by 23
“The effect looks to be increasing over time with a dose-dependent effect, as a DMT is expected to determine [ 4].”
Alzheimer's Disease - A Comprehensive Review
Woźniak, K., Gardian-Baj, M., Jung, M., Hedesz, P., Jung, M., Żuk‐Łapan, A., Doryń, A., Jędral, K., Włodarczyk, A., Szczerbiak, A., et al. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.56.013 · Cited by 21
“[19]”
NMR studies of amyloid interactions
Middleton, D. A. (2024) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2024.07.001 · Cited by 22
Chaudhuri, S., Cho, M., Stumpff, J., Bice, P. J., İş, Ö., Ertekin‐Taner, N., Saykin, A. J., & Nho, K. T. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00798-0 · Cited by 22
“After decades of clinical trial failure associated with anti-amyloid immunotherapy treatments for AD, [3–7] the recent FDA approval of lecanemab and donanemab as disease modifying therapies mark a significant break-through in the field [8].”
Transcranial Direct Current Stimulation Intervention in Alzheimer’s Disease and Its Follow-Up
Meléndez, J. C., Satorres, E., Pitarque, A., Escudero, J. V., Delhom, I., & Navarro, A. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230826 · Cited by 21
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders
Niazi, S. K., Mariam, Z., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126683 · Cited by 17
“Adu-canumab’s approval was significant as it was the first disease-modifying therapy (DMT) for AD approved in two decades [33].”
BackgroundMathematical models on Alzheimer's disease and its treatment: A review
Maji, M., & Khajanchi, S. (2025) · Physics of Life Reviews · doi:10.1016/j.plrev.2025.01.004 · Cited by 19
Menéndez‐González, M., Tamba, B.-I., Leclere, M., Mabrouk, M., Schreiner, T. G., Ciobanu, R. C., & Tomás‐Zapico, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030768 · Cited by 16
“Despite a myriad of studies, no effective disease-modifying treatment is available at the present for most of these conditions [76] while the first disease-modifying therapies for AD have been recently approved with some controversy regarding their efficacy and safety [77,78].”
BackgroundZhao, T., & Jia, J. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14581 · Cited by 17
Vaziri, Y., Olia, J. B. H., Avcı, Ç. B., & Nourazarian, A. (2025) · Molecular Brain · doi:10.1186/s13041-025-01263-1 · Cited by 20
An inclusive study of recent advancements in Alzheimer's disease: A comprehensive review
Singh, S., Mahajan, M., Kumar, D., Singh, K., Chowdhary, M., & Amit (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102369 · Cited by 17
Alzheimer's Disease: Status of Low‐Dimensional Nanotherapeutic Materials
Huang, D., Liao, W., Li, J., Chen, T., Wang, X., Zhao, R., Zhang, L., Yu, X., Zheng, D., & Luan, P. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302015 · Cited by 15
Ehlbeck, J. T., Grimard, D. M., Hacker, R. M., Garcia, J. A., Wall, B. J., Bothwell, P. J., Jones, M. A., & Webb, M. I. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112424 · Cited by 15
Targeting the molecular web of Alzheimer’s disease: unveiling pathways for effective pharmacotherapy
Jadhav, D., Saraswat, N., Vyawahare, N. S., & Shirode, D. S. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00775-8 · Cited by 19
“Additionally, getting rid of it could make other brain functions run more effectively [119].”
BackgroundFocusing on earlier diagnosis of Alzheimer's disease
Frederiksen, K. S., Morató, X., Zetterberg, H., Gauthier, S. G., Boada, M., Pytel, V., Hahn-Pedersen, J. H., Tarazona, L. R. S., & Mattke, S. (2024) · Future Neurology · doi:10.2217/fnl-2023-0024 · Cited by 28
Perneczky, R., Darby, D., Frisoni, G. B., Hyde, R., Iwatsubo, T., Mummery, C. J., Park, K. H., van Beek, J., van der Flier, W. M., & Jessen, F. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100096 · Cited by 19
Self-citationTeipel, S. J., Temp, A. G. M., & Lutz, M. W. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12454 · Cited by 18
Proteostasis as a fundamental principle of Tau immunotherapy
Cruz, E., Nisbet, R. M., Padmanabhan, P., Waardenberg, A. J., Graham, M. E., Nkajja, G., Tapaswi, S., Connor, B. J., Robinson, P., & Götz, J. (2024) · Brain · doi:10.1093/brain/awae254 · Cited by 17
Adaptive immunity in the neuroinflammation of Alzheimer’s disease
Liu, H., Chen, Y., Zhang, J., & Chen, X. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003695 · Cited by 15
“[142] However, studies have indicated that antibodies such as aducanumab, lecanemab, and donanemab can cause amyloid-related imaging abnormalities (ARIAs), including brain swelling (ARIA-E) and microhemorrhages (ARIA-H), [143] and adverse reactions such as autoimmune responses and…”
Kechko, O. I., Adzhubei, A. A., Tolstova, A. P., Indeykina, M. I., Popov, I. A., Zhokhov, S. S., Gnuchev, N. V., Mitkevich, V. A., Makarov, A. А., & Kozin, S. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411241 · Cited by 12
“However, monoclonal antibodies have many side effects [5]; therefore, the search for shorter functional Aβ fragments that can be used as drug targets for small molecular weight agents that specifically bind to Aβ through the targeted site and prevent the formation and spread of Aβ oligomers and/or aggregates remains h…”
BackgroundPersson, K., Barca, M. L., Edwin, T. H., Cavallin, L., Tangen, G. G., Rhodius‐Meester, H. F. M., Selbæk, G., Knapskog, A., & Engedal, K. (2024) · Brain and Behavior · doi:10.1002/brb3.3397 · Cited by 12
Multiple system atrophy with amyloid-β-predominant Alzheimer’s disease neuropathologic change
Kon, T., Ichimata, S., Luca, D. G. D., Martínez-Valbuena, I., Kim, A., Yoshida, K., Alruwaita, A. A., Kleiner, G., Strafella, A. P., Forrest, S. L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae141 · Cited by 13
“Furthermore, disease-modifying therapies targeting A β have been rapidly evolving 83,84 and could be considered for combined therapies in such cases.”
Wang, S., Qi, C., Rajpurohit, C. S., Ghosh, B., Xiong, W., Wang, B., Qi, Y., Hwang, S. H., Hammock, B. D., Li, H., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00844-x · Cited by 16
“Although anti-Aβ antibodies have shown clinical efficacy in prodromal AD [2, 3], NFTs correlates more closely with cognitive decline than Aβ plaques [4].”
Kihal, N., Nguyen, P. T., Nazemi, A., Greschner, A. A., Gauthier, M. A., & Bourgault, S. (2024) · Aggregate · doi:10.1002/agt2.502 · Cited by 12
Radiotherapy for non-cancer diseases: benefits and long-term risks
Thariat, J., Little, M. P., Zablotska, L. B., Samson, P. P., O’Banion, M. K., Leuraud, K., Bergom, C. R., Girault, G., Azimzadeh, O., Bouffler, S. D., et al. (2024) · International Journal of Radiation Biology · doi:10.1080/09553002.2023.2295966 · Cited by 15
“Importantly, amyloid plaque clearance alone is not likely to be beneficial for AD patients as demonstrated by the many failed trials of anti-amyloid therapies (Perneczky et al. 2023).”
BackgroundGroo, A., Curel, T., Malzert‐Fréon, A., Séguy, L., Bento, O., Corvaisier, S., Culerier, T., Legrand, R., Callizot, N., Henriques, A., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07599-7 · Cited by 11
“Formulation for in vitro and in vivo evaluation: Results See Supplementary tables 4, 5.”
Pardo, K., Khasminsky, V., Keret, O., Benninger, F., Goldberg, I., Shelef, I., Auriel, E., & Glik, A. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14551 · Cited by 13
“47 Further benefits could be achieved by improving our understanding of the mechanisms behind amyloid production–clearance mismatch 48 while exploring ways to prevent decreased clearance rates due to venous insufficiency.”
Alzheimer's Targeted Treatments: Focus on Amyloid and Inflammation
Iwatsubo, T., Irizarry, M. C., Lewcock, J. W., & Carrillo, M. C. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1576-23.2023 · Cited by 10
Trares, K., Wiesenfarth, M., Stocker, H. R., Perna, L., Petrera, A., Hauck, S. M., Beyreuther, K. T., Brenner, H., & Schöttker, B. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00427-2 · Cited by 12
Global experience in brain amyloid imaging
Filippi, L., & Schillaci, O. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.03.004 · Cited by 12
Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial
Kutzsche, J., Cosma, N. C., Kauselmann, G., Fenski, F., Bieniek, C., Bujnicki, T., Pils, M., Bannach, O., Willbold, D., & Peters, O. (2025) · Nature Communications · doi:10.1038/s41467-025-59295-z · Cited by 13
“…both ef fi cacy and risk for potentially serious adverse events like ARIA-E or ARIA-H 20 , as lecanemab, for which it has been claimed to preferentially target soluble A β proto fi brils, has the lower risk-bene fi t-ratio compared to aducanumab, which targets A β oligomers and A β plaques 21 .”
Self-citationProduction and N-glycan engineering of Varlilumab in Nicotiana benthamiana
Nguyen, K. D., Kajiura, H., Kamiya, R., Yoshida, T., Misaki, R., & Fujiyama, K. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1215580 · Cited by 11
“The use of therapeutic monoclonal antibodies for the treatment of cancers, Alzheimer’s disease, and other conditions (Perneczky et al., 2023) has increased substantially over the past years (Kaplon et al.”
BackgroundLecanemab: Appropriate Use Recommendations — A Commentary from a European Perspective
Frölich, L., & Jessen, F. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.44 · Cited by 9
Self-citationLobos, P., Vega-Vásquez, I., Bruna, B., Gleitze, S., Toledo, J. A., Härtel, S., Hidalgo, C., & Paula-Lima, A. C. (2023) · Antioxidants · doi:10.3390/antiox12111972 · Cited by 9
“Recently, several clinical trials using monoclonal antibodies that target amyloid plaques or A β Os in early AD have shown positive results and even obtained approval, although with important clinical efficacy and safety issues [108–110].”
Bhalala, O. G., Thompson, J., Watson, R., & Yassi, N. (2024) · The Medical Journal of Australia · doi:10.5694/mja2.52359 · Cited by 9
Mosalam, E. M., Elberri, A. I., Abdallah, M. S., Abdel‐Bar, H. M., Zidan, A. A., Batakoushy, H. A., & Mansour, H. E. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147790 · Cited by 11
“For instance, anti-amyloid agents aim to reduce A β production, promote A β clearance, or disrupt A β aggregation, while anti-tau therapies seek to stabilize or inhibit the hyperphosphorylation of tau, thereby preventing the formation of neurofib-rillary tangles [9,10].”
BackgroundLi, Y., Zhang, J., Ma, B., Yu, W., Xu, M., Luan, W., Yu, Q., Zhang, L., Rong, R., Fu, Y., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124786 · Cited by 11
Deep learning-based denoising for unbiased analysis of morphology and stiffness in amyloid fibrils
Park, J., Cheong, D. Y., Lee, G., & Han, C. E. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109410 · Cited by 10
Lin, H.-C., & Lane, H. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03492-3 · Cited by 9
Big versus small: The impact of aggregate size in disease
Hnath, B., Chen, J., Reynolds, J., Choi, E. S., Wang, J., Zhang, D., Sha, C. M., & Dokholyan, N. V. (2023) · Protein Science · doi:10.1002/pro.4686 · Cited by 8
“In the past year, two different monoclonal antibody treatments targeting Aβ oligomers were given emergency FDA approval to treat AD (Aducanumab and Lecanemab; Marsool et al., 2023; Perneczky et al., 2023; Rahman et al., 2023; Vitek et al., 2023).”
BackgroundStatsenko, Y. A., Habuza, T., Smetanina, D., Simiyu, G. L., Meribout, S., King, F. C., Gelovani, J. G., Das, K. M., Gorkom, K., Zaręba, K. T., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11071999 · Cited by 9
Blood-Based Biomarkers for Early Alzheimer’s Disease Diagnosis in Real-World Settings
Perneczky, R., Hansen, N., Hofmann, A., Laske, C., Priller, J., Grimmer, T., Frölich, L., Düzel, E., Jessen, F., & Wiltfang, J. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3774-6_1 · Cited by 14
Self-citationMa, M., Wang, J., Zhong, W., Li, Z., & Zhao, Y. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202517917 · Cited by 11
Fluid Biomarkers in Dementia Diagnosis
Quinn, J. F., & Gray, N. E. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001497 · Cited by 8
Davidson, C. E. D., & Prakash, R. (2025) · Biosensors · doi:10.3390/bios15040228 · Cited by 7
“Recent advances in Alzheimer’s disease research reveal a promising association between anti-amyloid therapeutics and lifestyle changes in slowing down and mitigating the neurodegeneration and cognitive decline associated with AD [3–6].”
Tiwari, P., Dwivedi, R., Kaushik, M., Tripathi, M., & Dada, R. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02363-2 · Cited by 10
“This would allow for timely interventions when potential treatments may be more effective (R et al. 2023).”
Yang, S. J., Lim, J., Choi, Y., Kim, H. S., Kim, S. J., Lee, J., & Suh, C. H. (2026) · Journal of Clinical Neurology · doi:10.3988/jcn.2025.0324 · Cited by 8
Air pollution amyloidogenesis is attenuated by the gamma‐secretase modulator GSM‐15606
Godoy-Lugo, J. A., Thorwald, M. A., Cacciottolo, M., D’Agostino, C., Chakhoyan, A., Sioutas, C., Tanzi, R. E., Rynearson, K. D., & Finch, C. E. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14086 · Cited by 6
“41,42”
Regional health priorities for dementia: a roadmap for the Western Pacific
Timmins, H. C., Mok, V., Kim, S. H., Shahrizaila, N., Sung, J., Sobue, G., Agustini, S., Ward, S., Anstey, K. J., Talbot, D.-L., et al. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101179 · Cited by 14
“36 The considerable cultural diversity across the Western Paci fi c also has implications for dementia care services.”
BackgroundYang, C.-H., Li, C., Sie, Y.-Y., Chen, L., Yuan, Y.-H., & Hou, W. (2024) · Botanical studies · doi:10.1186/s40529-024-00443-x · Cited by 8
“…the small molecules targeting processing enzymes associated with amyloid β peptide generations or macromolecules of humanized anti-amyloid monoclonal antibodies most were failed to improve cognition function (McGleenon et al. 1999; Čolović et al. 2013; Perneczky et al. 2023; Cummings et al. 2024).”
Faustmann, T. J., Corvace, F., Faustmann, P. M., & Ismail, F. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1522128 · Cited by 11
Xia, M., Ling, C., Ye, H., Liang, S., Cao, Q., Wang, W., Zhang, C., Dong, Z., Tian, M., Zuo, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544299 · Cited by 7
Roles and therapeutic potential of PARP-1 in neurodegenerative diseases
Liu, C., Lai, F., Zhang, T., Mao, K., Wan, H., & He, Y. T. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117373 · Cited by 8
Beyond Alzheimer’s disease—translating biomarker insights across CNS diseases
Brady, L. S., Mahinrad, S., Edelmayer, R. M., Potter, W. Z., Hutten, S. J., Anticevic, A., Taylor‐Burds, C., Winston, C. N., Coetzee, T., Paulsen, J. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr2511 · Cited by 9
Programming extracellular protein fate with peptide chimeras
Liao, J., Lin, Z., & Chuang, L. I. U. (2026) · Chem · doi:10.1016/j.chempr.2026.103040 · Cited by 15
Mind the Metabolic Gap: Bridging Migraine and Alzheimer's disease through Brain Insulin Resistance
Moro, L. D., Pirovano, E., & Rota, E. (2024) · Aging and Disease · doi:10.14336/ad.2024.0351 · Cited by 12
“Indeed, there are still numerous hurdles to overcome to improve their long-term efficacy, safety and accessibility [10–12].”
How will the emergence of lecanemab change dementia treatment?
Iwata, A. (2024) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14945 · Cited by 7
“5”
Yang, Y., Qiu, H., Fan, Y., Zhang, Q., Qin, H., Wu, J., Zhang, X., Liu, Y., Zhou, R., Zhang, Q., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01584-8 · Cited by 8
Clinically meaningful benefit and real‐world evidence in Alzheimer's disease research and care
Perneczky, R., & Froelich, L. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70090 · Cited by 12
Self-citationThe association of microbial infection and adaptive immune cell activation in Alzheimer’s disease
Clement, M. (2023) · Discovery Immunology · doi:10.1093/discim/kyad015 · Cited by 6
“There is no current cure for AD, but recent exciting advances have been made that focus on new immunotherapy-based anti-A β antibody treatments [5, 6].”
BackgroundRen, J., Jepson, C. E., Nealy, S. L., Kuhlmann, C. J., Osuka, S., Azolibe, S. U., Blucas, M. T., Nagaoka-Kamata, Y., Kharlampieva, E., & Kamata, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1214118 · Cited by 6
Brain Age Estimation on a Dementia Cohort Using FLAIR MRI Biomarkers
Crystal, O. R., Maralani, P. J., Black, S. E., Fischer, C. E., Moody, A. R., & Khademi, A. (2023) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8059 · Cited by 6
Redesigning the kinetics of lysozyme amyloid aggregation by cephalosporin molecules
Muthu, S. A., Qureshi, A., Sharma, R., Bisaria, I., Parvez, S., Grover, S., & Ahmad, B. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2335304 · Cited by 8
“This lead the drug development modules to focus on and investigate the amyloid cascade and aggregation inhibitors for arresting disease progression (Perneczky et al., 2023; Rajan et al., 2021; Shi et al., 2020).”
Yan, J., Yang, X., Li, G., Ramírez, O. A., Hagenston, A. M., Chen, Z.-Y., & Bading, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03143-5 · Cited by 6
“In-depth knowledge of the disease mechanism is essential for developing therapeutic interventions [1, 2].”
ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner
Steward, A., Dewenter, A., Hirsch, F., Roemer, S. N., Zhu, Z., Dehsarvi, A., Biel, D., Klonowski, M., Frontzkowski, L. K., Palleis, C., et al. (2025) · Brain · doi:10.1093/brain/awaf463 · Cited by 6
Metadata
- Authors
- Perneczky, R., Jessen, F., Grimmer, T., Levin, J., Flöel, A., Peters, O., & Froelich, L.
- Affiliations
- German Center for Neurodegenerative Diseases (DE)
- University of Cologne (DE)
- TUM Klinikum (DE)
- Universitätsmedizin Greifswald (DE)
- Central Institute of Mental Health (DE)
- Corresponding author
- Perneczky, Robert
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-01-19
- Volume
- 146
- Issue
- 3
- Pages
- 842-849
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4317401758
- Cited by
- 182
- References
- 40
- Citations by year
- 2026: 33 · 2025: 50 · 2024: 57 · 2023: 42
- FWCI
- 32.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- VERUM Foundation
- Sheffield National Institute for Health Research
- Biomedical Research Centre
- University of Cambridge—Ludwig-Maximilians-University Munich Strategic Partnership
- Hector II Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, anti-amyloid monoclonal antibodies, amyloid-beta protofibrils, amyloid PET, disease-modifying therapy, clinical trial failure, antibody safety, blood-based biomarkers, case finding, early Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Biomarkers, Amyloid beta-Peptides, Treatment Outcome, Disease Progression, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.